Biology subjects

Zitnik, M.

Publications and source records attributed to Zitnik, M..

22 records · Page 2Linked to original sources

bioRxiv2018

Prioritizing network communities

Uncovering modular structure in networks is fundamental for systems in biology, physics, and engineering. Community detection identifies candidate modules as hypotheses, which then need to be validated through experiments, such as mutagenesis in a biological laboratory. Only a few communities can typically be validated, and it is thus important to prioritize which communities to select for downstream experimentation. Here we develop CRO_SCPCAPANKC_SCPCAP, a mathematically principled approach for prioritizing network communities. CRO_SCPCAPANKC_SCPCAP efficiently evaluates robustness and magnitude of structural features of each community and then combines these features into the community prioritization. CRO_SCPCAPANKC_SCPCAP can be used with any community detection method. It needs only information provided by the network structure and does not require any additional metadata or labels. However, when available, CRO_SCPCAPANKC_SCPCAP can incorporate domain-specific information to further boost performance. Experiments on many large networks show that CRO_SCPCAPANKC_SCPCAP effectively prioritizes communities, yielding a nearly 50-fold improvement in community prioritization.

bioinformatics↗

bioRxiv2018

Modeling polypharmacy side effects with graph convolutional networks

Motivation: The use of drug combinations, termed polypharmacy, is common to treat patients with complex diseases or co-existing conditions. However, a major consequence of polypharmacy is a much higher risk of adverse side effects for the patient. Polypharmacy side effects emerge because of drug-drug interactions, in which activity of one drug may change, favorably or unfavorably, if taken with another drug. The knowledge of drug interactions is often limited because these complex relationships are rare, and are usually not observed in relatively small clinical testing. Discovering polypharmacy side effects thus remains an important challenge with significant implications for patient mortality and morbidity.\n\nResults: Here, we present Decagon, an approach for modeling polypharmacy side effects. The approach constructs a multimodal graph of protein-protein interactions, drug-protein target interactions, and the polypharmacy side effects, which are represented as drug-drug interactions, where each side effect is an edge of a different type. Decagon is developed specifically to handle such multimodal graphs with a large number of edge types. Our approach develops a new graph convolutional neural network for multirelational link prediction in multimodal networks. Unlike approaches limited to predicting simple drug-drug interaction values, Decagon can predict the exact side effect, if any, through which a given drug combination manifests clinically. Decagon accurately predicts polypharmacy side effects, outperforming baselines by up to 69%. We find that it automatically learns representations of side effects indicative of co-occurrence of polypharmacy in patients. Furthermore, Decagon models particularly well polypharmacy side effects that have a strong molecular basis, while on predominantly non-molecular side effects, it achieves good performance because of effective sharing of model parameters across edge types. Decagon opens up opportunities to use large pharmacogenomic and patient population data to flag and prioritize polypharmacy side effects for follow-up analysis via formal pharmacological studies.\n\nAvailability: Source code and preprocessed datasets are at: http://snap.stanford.edu/decagon.\n\nContact: jure@cs.stanford.edu

bioinformatics↗

bioRxiv2018

Cross-type Biomedical Named Entity Recognition with Deep Multi-Task Learning

MotivationState-of-the-art biomedical named entity recognition (BioNER) systems often require handcrafted features specific to each entity type, such as genes, chemicals and diseases. Although recent studies explored using neural network models for BioNER to free experts from manual feature engineering, the performance remains limited by the available training data for each entity type.\n\nResultsWe propose a multi-task learning framework for BioNER to collectively use the training data of different types of entities and improve the performance on each of them. In experiments on 15 benchmark BioNER datasets, our multi-task model achieves substantially better performance compared with state-of-the-art BioNER systems and baseline neural sequence labeling models. Further analysis shows that the large performance gains come from sharing character- and word-level information among relevant biomedical entities across differently labeled corpora.\n\nAvailabilityOur source code is available at https://github.com/yuzhimanhua/lm-lstm-crf.\n\nContactxwang174@illinois.edu, xiangren@usc.edu.

bioinformatics↗

bioRxiv2017

Large-Scale Analysis of Disease Pathways in the Human Interactome

Discovering disease pathways, which can be defined as sets of proteins associated with a given disease, is an important problem that has the potential to provide clinically actionable insights for disease diagnosis, prognosis, and treatment. Computational methods aid the discovery by relying on protein-protein interaction (PPI) networks. They start with a few known disease-associated proteins and aim to find the rest of the pathway by exploring the PPI network around the known disease proteins. However, the success of such methods has been limited, and failure cases have not been well understood. Here we study the PPI network structure of 519 disease pathways. We find that 90% of pathways do not correspond to single well-connected components in the PPI network. Instead, proteins associated with a single disease tend to form many separate connected components/regions in the network. We then evaluate state-of-the-art disease pathway discovery methods and show that their performance is especially poor on diseases with disconnected pathways. Thus, we conclude that network connectivity structure alone may not be sufficient for disease pathway discovery. However, we show that higher-order network structures, such as small subgraphs of the pathway, provide a promising direction for the development of new methods.

bioinformatics↗